BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23267806)

  • 1. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.
    Rao V; Haywood S; Abecassis M; Levitsky J
    Transplant Proc; 2013; 45(1):320-2. PubMed ID: 23267806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis.
    Zahn A; Müeller F; Hinz U; Schemmer P; Stremmel W; Ganten T
    Ann Transplant; 2013 Oct; 18():525-32. PubMed ID: 24088725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
    Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.
    Shao ZY; Yan LN; Wang WT; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
    World J Gastroenterol; 2012 Mar; 18(9):991-8. PubMed ID: 22408361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients.
    Yoo MC; Vanatta JM; Modanlou KA; Campos L; Nezakatgoo N; Nair S; Eason JD
    Transplantation; 2015 Jun; 99(6):1231-5. PubMed ID: 25539464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
    Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience.
    Dumortier J; Guillaud O; Pittau G; Salandre J; Adham M; Scoazec JY; Boillot O
    Transplant Proc; 2010 Sep; 42(7):2602-6. PubMed ID: 20832553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
    Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
    World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
    Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
    Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
    Groetzner J; Kaczmarek I; Schirmer J; Uberfuhr P; Gulbins H; Daebritz S; Meiser B; Reichart B
    Clin Transplant; 2008; 22(5):587-93. PubMed ID: 18460000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.